Ngwe Tun M, Nwe K, Balingit J, Takamatsu Y, Inoue S, Pandey B
Vaccines (Basel). 2023; 11(12).
PMID: 38140260
PMC: 10748371.
DOI: 10.3390/vaccines11121857.
Akram M, Hameed S, Hassan A, Khan K
Curr Med Chem. 2023; 31(16):2195-2233.
PMID: 37723635
DOI: 10.2174/0929867331666230918110144.
de Moraes J, Riediger I, Crosewski F, Garrett D, Fantinato F, Ribeiro K
Lancet Reg Health Am. 2023; 7:100141.
PMID: 36777647
PMC: 9904136.
DOI: 10.1016/j.lana.2021.100141.
Pinto P, Barros T, Lima L, Pacheco A, Assis M, Pereira B
Viruses. 2022; 14(7).
PMID: 35891431
PMC: 9323404.
DOI: 10.3390/v14071452.
Castillo J, Giraldo D, Hernandez J, Smit J, Rodenhuis-Zybert I, Urcuqui-Inchima S
PLoS Negl Trop Dis. 2021; 15(10):e0009873.
PMID: 34634046
PMC: 8530315.
DOI: 10.1371/journal.pntd.0009873.
Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
VanBlargan L, Milutinovic P, Goo L, DeMaso C, Durbin A, Whitehead S
J Virol. 2021; 95(23):e0095621.
PMID: 34549976
PMC: 8577358.
DOI: 10.1128/JVI.00956-21.
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation.
Sharp T, Anderson K, Katzelnick L, Clapham H, Johansson M, Morrison A
Lancet Infect Dis. 2021; 22(2):e42-e51.
PMID: 34265259
PMC: 11379041.
DOI: 10.1016/S1473-3099(20)30871-9.
Dengvaxia: the world's first vaccine for prevention of secondary dengue.
Tully D, Griffiths C
Ther Adv Vaccines Immunother. 2021; 9:25151355211015839.
PMID: 34036241
PMC: 8132086.
DOI: 10.1177/25151355211015839.
The use of mobile phones for the prevention and control of arboviral diseases: a scoping review.
Carrillo M, Kroeger A, Cardenas Sanchez R, Monsalve S, Runge-Ranzinger S
BMC Public Health. 2021; 21(1):110.
PMID: 33422034
PMC: 7796697.
DOI: 10.1186/s12889-020-10126-4.
Well-balanced immune response and protective efficacy induced by a single dose of live attenuated tetravalent dengue vaccine (KD-382) in monkeys.
Yoshimura M, Shinmura Y, Takagi S, Kameyama K, Sonoda K, Koide F
Heliyon. 2020; 6(7):e04506.
PMID: 32760828
PMC: 7393427.
DOI: 10.1016/j.heliyon.2020.e04506.
Dengue in parts of the Guinea Savannah region of Nigeria and the risk of increased transmission.
Omatola C, Onoja A, Moses E, Mahmud M, Mofolorunsho C
Int Health. 2020; 13(3):248-252.
PMID: 32562421
PMC: 8079312.
DOI: 10.1093/inthealth/ihaa033.
Optimal control approaches for combining medicines and mosquito control in tackling dengue.
Rawson T, Wilkins K, Bonsall M
R Soc Open Sci. 2020; 7(4):181843.
PMID: 32431854
PMC: 7211884.
DOI: 10.1098/rsos.181843.
Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial.
Turner M, Papadimitriou A, Winkle P, Segall N, Levin M, Doust M
Hum Vaccin Immunother. 2020; 16(10):2456-2464.
PMID: 32119591
PMC: 7644226.
DOI: 10.1080/21645515.2020.1727697.
Broad dengue neutralization in mosquitoes expressing an engineered antibody.
Buchman A, Gamez S, Li M, Antoshechkin I, Li H, Wang H
PLoS Pathog. 2020; 16(1):e1008103.
PMID: 31945137
PMC: 6964813.
DOI: 10.1371/journal.ppat.1008103.
Designing a polytope for use in a broad-spectrum dengue virus vaccine.
Himmah K, Fitriyah , Ardyati T, Afiyanti M, Rifai M, Widodo
J Taibah Univ Med Sci. 2019; 13(2):156-161.
PMID: 31435318
PMC: 6695032.
DOI: 10.1016/j.jtumed.2017.11.002.
Serostatus testing and dengue vaccine cost-benefit thresholds.
Pearson C, Abbas K, Clifford S, Flasche S, Hladish T
J R Soc Interface. 2019; 16(157):20190234.
PMID: 31431184
PMC: 6731500.
DOI: 10.1098/rsif.2019.0234.
A novel interaction between dengue virus nonstructural protein 1 and the NS4A-2K-4B precursor is required for viral RNA replication but not for formation of the membranous replication organelle.
Plaszczyca A, Scaturro P, Neufeldt C, Cortese M, Cerikan B, Ferla S
PLoS Pathog. 2019; 15(5):e1007736.
PMID: 31071189
PMC: 6508626.
DOI: 10.1371/journal.ppat.1007736.
Thioguanine-based DENV-2 NS2B/NS3 protease inhibitors: Virtual screening, synthesis, biological evaluation and molecular modelling.
Hariono M, Choi S, Roslim R, Nawi M, Tan M, Kamarulzaman E
PLoS One. 2019; 14(1):e0210869.
PMID: 30677071
PMC: 6345492.
DOI: 10.1371/journal.pone.0210869.
Customers' preferences and willingness to pay for a future dengue vaccination: a study of the empirical evidence in Vietnam.
Vo T, Tran Q, Vo N
Patient Prefer Adherence. 2018; 12:2507-2515.
PMID: 30568429
PMC: 6267625.
DOI: 10.2147/PPA.S188581.
Feasibility and willingness to pay for dengue vaccine in the threat of dengue fever outbreaks in Vietnam.
Nguyen L, Tran B, Do C, Hoang C, Nguyen T, Dang T
Patient Prefer Adherence. 2018; 12:1917-1926.
PMID: 30288032
PMC: 6163003.
DOI: 10.2147/PPA.S178444.
